Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirbanibulin vs Diclofenac in Actinic Keratosis
NCT05387525Phase 4Active, not recruiting
- Sponsor
- Almirall
- Start
- Oct 2022
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 4, randomised, single-blind trial of tirbanibulin in actinic keratosis (AK) (2 arms), sponsored by Almirall. Primary endpoint: Percentage of Participants with Histologically Confirmed Invasive Squamous Cell Carcinoma (SCC) in the Treatment Field (TF) at 3 years. Started Oct 2022; status: active, not recruiting.
02
Drugs
tirbanibulin
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT05387525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05387525.